Compare RPAY & LFCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RPAY | LFCR |
|---|---|---|
| Founded | 2006 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.4M | 269.8M |
| IPO Year | 2018 | 1996 |
| Metric | RPAY | LFCR |
|---|---|---|
| Price | $2.99 | $3.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $5.58 | $5.50 |
| AVG Volume (30 Days) | ★ 1.3M | 448.3K |
| Earning Date | 03-09-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $309,261,000.00 | ★ $557,559,000.00 |
| Revenue This Year | $12.20 | $2.32 |
| Revenue Next Year | $5.24 | $11.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 6.36 |
| 52 Week Low | $2.56 | $3.64 |
| 52 Week High | $5.90 | $8.98 |
| Indicator | RPAY | LFCR |
|---|---|---|
| Relative Strength Index (RSI) | 52.18 | 17.68 |
| Support Level | $2.98 | N/A |
| Resistance Level | $3.28 | $8.62 |
| Average True Range (ATR) | 0.16 | 0.43 |
| MACD | 0.05 | -0.07 |
| Stochastic Oscillator | 60.39 | 4.45 |
Repay Holdings Corp is a payments technology company. It provides integrated payment processing solutions to industry-oriented vertical markets in which businesses or other organizations have specific transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments. The company generates majority of its revenue from Consumer Payments segment.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.